Merck Axes Two Cancer Candidates After Disappointing Late
1 day ago · Merck announced on Monday that it will discontinue the development of two cancer assets, vibostolimab and favezelimab, following underwhelming Phase III data. The pharma was studying both candidates as combination treatments with the blockbuster therapy Keytruda (pembrolizumab). Vibostolimab is a monoclonal antibody that works by blocking the TIGIT pathway, in turn restoring the immune system ...
Merck discontinues clinical development programs for …
21 hours ago · Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody.Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KeyVibe program.. Favezelimab is being evaluated as an investigational ...
Merck Discontinues Certain Cancer Candidate Trials After Futility ...
2 days ago · Merck to discontinue vibostolimab and favezelimab programs after futility in Phase 3 trials for NSCLC and Hodgkin lymphoma. FDA to decide on Merck's RSV antibody, clesrovimab, by June 10, 2025 ...
Merck calls quits on two immunotherapies for cancer
3 days ago · According to Merck, emerging findings from trials of vibostolimab and favezelimab led it to scrap each. Following an interim check of two Phase 3 lung cancer studies, trial monitors found the Keytruda-vibostolimab combination met a pre-specified “futility criteria,” meaning patients who’d received it were unlikely to live longer than ...
Vibostolimab/Favezelimab Clinical Programs in …
2 days ago · Clinical development programs including the KeyVibe program investigating the anti–TIGIT antibody vibostolimab and the KEYFORM program investigating the anti–LAG-3 agent favezelimab have been discontinued, according to a press release from the developer, Merck. 1 Data analyses for the phase 3 trials remain ongoing, and results, upon finalization, will be shared with the scientific community.
Merck Discontinues Certain Cancer Candidate Trials After Futility
2 days ago · Favezelimab is being evaluated as an investigational fixed-dose combination with pembrolizumab in the KEYFORM program. Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which ...
Merck Ends Development of Two Experimental Cancer Drugs
1 day ago · Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively ...
What can we help you find? - Merck
2 days ago · About favezelimab Favezelimab (MK-4280) is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody. LAG-3 is a cell surface immunomodulatory receptor expressed on various immune cells that down-regulates T cell proliferation and activation. ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes ...
Merck (MRK) Provides Update on KeyVibe and KEYFORM Clinical …
2 days ago · FREE Breaking News Alerts from StreetInsider.com! E-mail Address. StreetInsider.com Top Tickers, 12/16/2024 ... Separately, Merck has decided to end the favezelimab clinical development program ...
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late …
Sep 25, 2024 · On Wednesday, Merck & Co Inc (NYSE: MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for...